Amid challenges, generics industry gets FDA assist to ID new areas of need

As the generics industry squares off against price deflation, manufacturers are looking for new product areas in need of lower-cost alternatives — and recent Food and Drug Administration efforts are helping with the discovery process.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.